Ki Wook Yun

Abstract Community-acquired pneumonia (CAP) remains a leading cause of hospitalization and antibiotic use in children, yet etiologic data during Mycoplasma pneumoniae epidemic periods—now resurging globally after the COVID-19 pandemic—remain scarce. We conducted a nationwide prospective surveillance study across 17 hospitals in Korea between September 2023 and May 2025, enrolling 740 children with CAP.

Although the proportion of children among the confirmed COVID-19 cases has increased with a relatively high vaccination rate in adults and the circulation of delta-variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, children generally have an uncomplicated clinical course of COVID-19 [Reference Pediatrics1]. However, high-risk children, including immunocompromised patients, could have more severe disease when infected with SARS-CoV-2 [Reference Ouldali2].

There are a number of errors in the caption for Fig 4, “Multilocus sequence type and PspA clade for the serogroup 6 pneumococci.” Please see the complete, correct Fig 4 caption here. Fig 4. Multilocus sequence type and PspA clade in serogroups 14 (A), 23 (B), 19 (C), and 6 (D) pneumococci. The number pneumococcal isolates (y-axis) in the corresponding sequence type (ST, x-axis) is presented with the PspA clade types (differentiated in color).